SARS-CoV-2 vaccination in IBD: more pros than cons

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Ferdinando, Rabaud, Christian, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816748/
https://www.ncbi.nlm.nih.gov/pubmed/33473178
http://dx.doi.org/10.1038/s41575-021-00420-w
_version_ 1783638504243200000
author D’Amico, Ferdinando
Rabaud, Christian
Peyrin-Biroulet, Laurent
Danese, Silvio
author_facet D’Amico, Ferdinando
Rabaud, Christian
Peyrin-Biroulet, Laurent
Danese, Silvio
author_sort D’Amico, Ferdinando
collection PubMed
description Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.
format Online
Article
Text
id pubmed-7816748
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78167482021-01-21 SARS-CoV-2 vaccination in IBD: more pros than cons D’Amico, Ferdinando Rabaud, Christian Peyrin-Biroulet, Laurent Danese, Silvio Nat Rev Gastroenterol Hepatol Comment Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders. Nature Publishing Group UK 2021-01-20 2021 /pmc/articles/PMC7816748/ /pubmed/33473178 http://dx.doi.org/10.1038/s41575-021-00420-w Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
D’Amico, Ferdinando
Rabaud, Christian
Peyrin-Biroulet, Laurent
Danese, Silvio
SARS-CoV-2 vaccination in IBD: more pros than cons
title SARS-CoV-2 vaccination in IBD: more pros than cons
title_full SARS-CoV-2 vaccination in IBD: more pros than cons
title_fullStr SARS-CoV-2 vaccination in IBD: more pros than cons
title_full_unstemmed SARS-CoV-2 vaccination in IBD: more pros than cons
title_short SARS-CoV-2 vaccination in IBD: more pros than cons
title_sort sars-cov-2 vaccination in ibd: more pros than cons
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816748/
https://www.ncbi.nlm.nih.gov/pubmed/33473178
http://dx.doi.org/10.1038/s41575-021-00420-w
work_keys_str_mv AT damicoferdinando sarscov2vaccinationinibdmoreprosthancons
AT rabaudchristian sarscov2vaccinationinibdmoreprosthancons
AT peyrinbirouletlaurent sarscov2vaccinationinibdmoreprosthancons
AT danesesilvio sarscov2vaccinationinibdmoreprosthancons

Ejemplares similares